Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly

Clinical Endocrinology

Volumn 63, Issue 3, 2005, Pages 342-349

  Colao, Annamaria ^a   Pivonello, Rosario ^a   Cappabianca, Paolo ^a   Briganti, Francesco ^a   Tortora, Fabio ^a   Auriemma, Renata S ^a   De Martino, Maria Cristina ^a   Marzullo, Paolo ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SEX HORMONE; SOMATOMEDIN; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE DURATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SEX HORMONE DETERMINATION; SLOW DRUG RELEASE; TUMOR VOLUME;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HUMANS; HYPOGONADISM; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SEX FACTORS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 24144467764     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02351.x     Document Type: Article

References (40)

1. Stewart, P.M., Kane, F.K., Stewart, S.E., Lancranjan, I. & Sheppard, M.C. (1995) Depot long-acting somatostatin analog (Sandostatin® LAR®) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3267-3272.
2. Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997) Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
3. Fløgstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1997) Sandostatin® LAR® in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23-28.
4. Gillis, J.C., Noble, S. & Goa, K.L. (1997) Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs, 53, 681-699.
5. Colao, A., Marzullo, P., Ferone, D., Marinò, V., Pivonello, R., Di Somma, C., Di Sarno, A., Giaccio, A. & Lombardi, G. (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. Journal of Endocrinological Investigation, 22, 40-47.
6. Lancranjan, I., Atkinson, A.B. & the Sandostatin® LAR® Group. (1999) Results of a European multicenter study with Sandostatin® LAR® in acromegalic patients. Pituitary, 1, 105-114.
7. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, M.L., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. & Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow-release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099-4103.
8. Colao, A., Marzullo, P., Ferone, D., Spinelli, L., Cuocolo, A., Bonaduce, D., Salvatore, M., Boerlin, V., Lancranjan, I. & Lombardi, G. (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 3132-3140.
9. Ferone, D., Colao, A., van der Lely, A.-J. & Lamberts, S.W.J. (2000) Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs, 17, 81-92.
10. Cannavò, S., Squadrito, S., Curtò, L., Almoto, B. & Trimarchi, F. (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Hormone and Metabolic Research, 33, 618-624.
11. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. & Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumour mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779-2786.
12. Ambrosio, M.R., Franceschetti, P., Bondanelli, M., Doga, M., Maffei, P., Baldelli, R., Tamburrano, G., Sicolo, N., Giustina, A. & degli Uberti, E.G. (2002) Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism, 51, 387-393.
13. Attanasio, R., Baldelli, R., Pivonello, R., Grottoli, S., Bocca, L., Gasco, V., Giusti, M., Tamburrano, G., Colao, A. & Cozzi, R. (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 88, 5258-5265.
14. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barasse, M., Albizzi, M., Dallabonzana, D. & Pedroncelli, A.M. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090-3098.
15. Amato, G., Mazziotti, G., Rotondi, M., Iorio, S., Doga, M., Sorvillo, F., Manganella, G., Di Salle, F., Giustina, A. & Carella, C. (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology, 56, 65-71.
16. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E., James, R.A., McConnell, M., Roberts, G.A., Scanion, M.F., Stewart, P.M., Teasdale, E., Turner, H.E., Wass, J., A. & Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism, 87, 4554-4563.
17. Lamberts, S.W.J. van der Lely, A.-J. de Herder, W.W. & Hofland, L.J. (1996) Octreotide. New England Journal of Medicine, 334, 246-254.
18. Gatford, K.L. Egan, A.R. Clarke, I.J. & Owens, P.C. (1998) Sexual dimorphism of the somatotrophic axis. Journal of Endocrinology, 157, 373-389.
19. Frantz, A.G. & Rabkin, M.T. (1965) Effects of estrogen and sex difference on secretion of human growth hormone. Journal of Clinical Endocrinology and Metabolism, 25, 1470-1480.
20. Ho, K.Y. Evans, W.S. Blizzard, R.M. Veldhuis, J.D. Merriam, G.R. Samojlik, E. Furlanetto, R. Rogol, A.D. Kaiser, D.L. & Thorner, M.O. (1987) Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. Journal of Clinical Endocrinology and Metabolism, 64, 51-58.
21. Thompson, R.G. Rodriguez, A. Kowarski, A. & Blizzard, R.M. (1972) Growth hormone: metabolic clearance rates, integrated concentrations, and production rates in normal adults and the effects of prednisone. Journal of Clinical Investigation, 51, 3193-3199.
22. Burman, P. Johansson, A. Siegbahn, A. Vesby, B. & Karlsson, F.A. (1997) Growth (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism, 82, 550-555.
23. Johansson, A.G. (1999) Gender difference in growth hormone response in adults. Journal of Endocrinological Investigation, 22, 58-60.
24. Colao, A. Amato, G. Pedroncelli, A. Baldelli, R. Grottoli, S. Gasco, V. Petretta, M. Carella, C. Pagani, G. Tamburrano, G. & Lombardi, G. (2002) Gender- and age-related difference in the endocrine parameters of acromegaly. Journal of Endocrinological Investigation, 25, 532-538.
25. Parkinson, C. Ryder, W.D. Trainer, P.J. Sensus Acromegaly Study Group (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. Journal of Clinical Endocrinology and Metabolism, 86, 5240-5204.
26. Edén Engström, B., Burman, P. & Karlsson, F.A. (2002) Men with acromegaly need higher doses of octreotide than women. Clinical Endocrinology, 56, 73-77.
27. Colao, A., Merola, B., Ferone, D. & Lombardi, G. (1997) Acromegaly. Journal of Clinical Endocrinology and Metabolism, 82, 2777-2781.
28. Colao, A. & Lombardi, G. (1998) Growth-hormone and prolactin excess. Lancet, 352, 1455-1461.
29. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., Von Werder, K. & Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526-529.
30. Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Merola, B., Salvatore, M. & Lombardi, G. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 81, 2356-2362.
31. Colao, A., Spinelli, L., Cuocolo, A., Spiezia, S., Pivonello, R., Di Somma, C., Bonaduce, D., Salvatore, M. & Lombardi, G. (2002) Cardiovascular consequences of early-onset growth hormone excess. Journal of Clinical Endocrinology and Metabolism, 87, 3097-3104.
32. Colao, A., Marzullo, P. & Lombardi, G. & the Multicenter Italian Study Group on Lanreotide (2002) Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. European Journal of Endocrinology, 146, 303-309.
33. Colao, A., Marzullo, P., Spiezia, S., Giaccio, A., Ferone, D., Cerbone, G., Di Sarno, A. & Lombardi, G. (2000) Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 85, 3754-3761.
34. Newman, C.B., Melmed, S., George, A., Torigian, D., Duhaney, M., Snyder, P., Young, W., Klibanski, A., Molitch, M.E., Gagel, R., Sheeler, L., Cook, D., Malarkey, W., Jackson, I., Vance, M.L., Barkan, A., Frohman, L. & Kleinberg, D.L. (1998) Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3034-3040.
35. van den Berg, G., Veldhuis, J.D., Frolich, M. & Roelfsema, F. (1996) An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. Journal of Clinical Endocrinology and Metabolism, 81, 2460-2467.
36. Cook, D.M., Ludlam, W.H. & Cook, M.B. (1999) Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 3956-3960.
37. Freda, P.U., Landman, R.E., Sundeen, R.E. & Post, K.D. (2001) Gender and age in the biochemical assessment of cure of acromegaly. Pituitary, 4, 163-171.
38. Zadik, Z., Chalew, S.A., McCarter, R.J. Jr, Meistas, M. & Kowarski, A.A. (1985) The influence of age on the 24 hour integrated concentration of growth hormone in normal individuals. Journal of Clinical Endocrinology and Metabolism, 60, 513-516.
39. Jaffe, C.A., Ocampo-Lim, B., Guo, W., Krueger, K., Sugahara, I., DeMott-Friberg, R., Bermann, M. & Barkan, A.L. (1998) Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation, 102, 153-164.
40. Kaltsas, G.A., Mukherjee, J.J., Jenkins, P.J., Satta, M.A., Islam, N., Monson, J.P., Besser, G.M. & Grossman, A.B. (1999) Menstrual irregularity in women with acromegaly. Journal of Clinical Endocrinology and Metabolism, 84, 2731-2735.